Erenumab in highly therapy-refractory migraine patients: First German real-world evidence

Overview of attention for article published in The Journal of Headache and Pain, July 2020

Altmetric Badge

Mentioned by

So far, Altmetric has seen 2 X posts from 2 X users, with an upper bound of 2,357 followers.

RT @NeuroPsychBMC: Erenumab in highly therapy-refractory migraine patients: First German real-world evidence https://t.co/8h6SQ0sNkI

Erenumab in highly therapy-refractory migraine patients: First German real-world evidence https://t.co/8h6SQ0sNkI

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.